Feb 13, 2018
On Thursday, January 25th, 2018, The Mastocytosis Society in collaboration with Blueprint Medicines hosted an informational webcast for the SM patient community about avapritinib (formerly known as BLU-285), an investigational medicine for people with advanced SM.
During the webcast, Dr. Andy Boral, Chief Medical Officer of Blueprint Medicines, shared an update on the avapritinib program, including a summary of updated clinical trial results recently presented at the American Society of Hematology annual meeting on December 10, 2017. Dr. Boral also provided an update on ongoing and planned avapritinib clinical trials for people with advanced, smoldering and indolent forms of SM.
A replay of the webcast is available on the “Patients” section of the Blueprint Medicines website under “Patient Community Events” located at: http://www.blueprintmedicines.com/patients/patient-community-events.
Questions may be submitted to Blueprint Medicines at email@example.com.